FDA Approves Sanofi's Venglustat (Infilbray) for Type 3 Gaucher Disease on Wednesday

The U.S. Food and Drug Administration approved Sanofi's oral drug venglustat (brand name Infilbray) on Wednesday, marking the first medication approved to treat Type 3 Gaucher disease, a rare genetic neurological disorder affecting the brain and nervous system. The drug crosses the blood-brain barrier to address progressive balance, coordination, speech, memory, and cognitive problems in Type 3 Gaucher patients by reducing the generation of fatty substances, differentiating it from enzyme replacement therapies like Cerezyme.
Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.